Syndax Pharmaceuticals (SNDX) Total Debt (2020 - 2024)

Syndax Pharmaceuticals' Total Debt history runs 4 years deep, the most recent figure standing at $343.7 million for Q4 2024.

• On a quarterly basis, Total Debt changed N/A year-over-year to $343.7 million in Q4 2024; TTM through Dec 2024 was $343.7 million, a N/A change from a year earlier, with the FY2024 full-year figure at $343.7 million, changed N/A from the prior year.
• Total Debt grew to $343.7 million in Q4 2024 per SNDX's latest filing, from $20.2 million in the prior quarter.
• Across five years, Total Debt topped out at $343.7 million in Q4 2024 and bottomed at $19.8 million in Q1 2020.
• The 4-year median for Total Debt is $20.1 million (2020), against an average of $49.5 million.
• Biggest YoY gain for Total Debt was 2.36% in 2021; the steepest drop was 1.11% in 2021.
• Year by year, Total Debt stood at $20.1 million in 2020, then decreased by 1.11% to $19.9 million in 2021, then rose by 1.56% to $20.2 million in 2022, then surged by 1600.89% to $343.7 million in 2024.
• Per Business Quant, the three latest SNDX Total Debt figures stand at $343.7 million (Q4 2024), $20.2 million (Q2 2022), and $20.0 million (Q1 2022).